TG Therapeutics, Inc. Logo

Email this page: News Release

TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma


Separate multiple addresses with commas. Maximum 200 characters.

These email addresses will be used to email the page on your behalf and will not be used by TG Therapeutics, Inc. for any marketing purposes.


This helps TG Therapeutics, Inc. prevent automated submissions.